Please note: The information displayed on this page might be outdated.
Triplet Therapeutics: Triplet is pursuing a transformative approach to develop treatments for repeat expansion disorders, a group of more than 40 known genetic diseases associated with expanded DNA nucleotide repeats including Huntington’s disease, myotonic dystrophy and various spinocerebellar ataxias. A significant body of human genetic evidence has identified that one central pathway, known as the DNA damage response pathway, drives onset and progression across this group of disorders. Triplet is developing antisense oligonucleotide (ASO) and small interfering RNA (siRNA) development candidates to precisely knock down key components of the DDR pathway that drive repeat expansion and potentially address repeat expansion disorders en masse.
US - New England
One Kendall Square, 1400W
Cambridge, MA 02139
Cambridge, MA 02139
Company Participants at Winter Private Company Showcase
Triplet Therapeutics, Director, Business Development & Strategy
Amar brings life science business development and corporate strategy experience to Triplet Therapeutics, Inc. Prior to joining Triplet, Amar was a management consultant in L.E.K. Consulting’s life sciences practice. While at L.E.K., Amar advised leading biotechnology and pharmaceutical companies on strategic planning, M&A, R&D, and business development strategy. Amar received his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology, where he studied RNA engineering for therapeutic and industrial applications. His research resulted in numerous publications in peer-reviewed journals, including Nucleic Acids Research.
Eric M. Sullivan
Triplet Therapeutics, CFO
Eric Sullivan is CFO of Triplet Therapeutics, Inc. and has more than 15 years of experience working in finance and operations at life sciences companies. Before joining Triplet, he led finance at Gemini Therapeutics and Oncorus, Inc. Previously Eric served as Vice President, Finance and Treasurer at bluebird bio and held various management positions at Merrimack Pharmaceuticals and PricewaterhouseCoopers. He received his undergraduate degree in accountancy from Bentley College and is a Certified Public Accountant in Massachusetts.
Triplet Therapeutics, Chief Executive Officer
Dr. Nessan Bermingham is a Co-Founder of Triplet Therapeutics and serves as its Chief Executive Officer, Board Member & President. He also serves as Advisor at Atlas Venture. He served as Board Member at Xilio Therapeutics. He is a Co-Founder of Intellia Therapeutics, where he served as President and Chief Executive Officer. He served as Board Observer at Lysosomal Therapeutics. He brings more than a decade's experience in life sciences investing across venture, public and secondary markets. His keen entrepreneurial vision inspired him to found Intellia. he has successfully co-founded numerous healthcare and biotech startup companies, including Ascelegen and Tal Medical. Prior to joining Atlas, he was a managing partner at Omega Funds and founder of Bio Equity Capital, a healthcare-focused special situations firm. He received his Ph.D. in Molecular Biology from Imperial College London, was a Howard Hughes Associate Fellow at Baylor College of Medicine and received his B.S. from Queen's University Belfast.